Serum HE4 levels combined with CE CT imaging improve the management of monitoring women affected by epithelial ovarian cancer

Oncology Reports

Volumn 30, Issue 5, 2013, Pages 2481-2487

  Manganaro, Lucia ^a   Michienzi, Simona ^a   Vinci, Valeria ^a   Falzarano, Renato ^a   Saldari, Matteo ^a   Granato, Teresa ^b   Viggiani, Valentina ^a   Frati, Luigi ^a   Anastasi, Emanuela ^a  

^a POLICLINICO UMBERTO I   (Italy)

^b CNR   (Italy)

Author keywords

Biomarker; Cancer antigen 125; CE CT; Epithelial ovarian cancer; Human epididymis protein 4

Indexed keywords

CA 125 ANTIGEN; HUMAN EPIDIDYMIS PROTEIN 4; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANTIGEN DETECTION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL INDICATOR; COMPUTED TOMOGRAPHY SCANNER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HUMAN; HUMAN CELL; IMAGE ANALYSIS; MULTIDETECTOR COMPUTED TOMOGRAPHY; OVARY CARCINOMA; PATIENT MONITORING; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; TIME SERIES ANALYSIS;

AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEINS; RECURRENCE; TOMOGRAPHY, EMISSION-COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 84885036593     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2682     Document Type: Article

References (32)

1. Kobayashi E, Ueda Y, Matsuzaki S, Yokoyama T, Kimura T, Yoshino K, Fujita M, Kimura T and Enomoto T: Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiol Biomarkers Prev 21: 1902-1912, 2012.
2. Berek JS, Crum C and Friedlander M: Cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 119 (Suppl 2): S118-S129, 2012.
3. Husseinzadeh N: Status of tumor markers in epithelial ovarian cancer has there been any progress? A review. Gynecol Oncol 120: 152-157, 2011.
4. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, Hellstrom I, Mok SC, Liu J and Bast RC Jr: Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecol Oncol 99: 267-277, 2005.
5. Bast RC Jr, Badgwell D, Lu Z, et al: New tumor markers: CA125 and beyond. Int J Gynecol Cancer 15 (Suppl 3): 274-281, 2005.
6. Medeiros LR, Rosa DD, da Rosa MI, et al: Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol 142: 99-105, 2009.
7. Kirchhoff C: Molecular characterization of epididymal proteins. Rev Reprod 3: 86-95, 1998.
8. Galgano MT, Hampton GM and Frierson HF Jr: Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 19: 847-853, 2006.
9. Hellström I, Raycraft J, Hayden-Ledbetter M, et al: The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 63: 3695-3700, 2003.
10. Li J, Dowdy S, Tipton T, Podratz K, Lu WG, Xie X and Jiang SW: HE4 as a biomarker for ovarian and endometrial cancer management. Expert Rev Mol Diagn 9: 555-566, 2009.
11. Anastasi E, Marchei GG, Viggiani V, et al: HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol 31: 113-119, 2010.
12. Moore RG and Maclaughlan S: Current clinical use of biomarkers for epithelial ovarian cancer. Curr Opin Oncol 22: 492-497, 2010.
13. Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB and McNeil BJ: Staging of advanced ovarian cancer: comparison of imaging modalities - report from the Radiological Diagnostic Oncology Group. Radiology 215: 761-767, 2000.
14. Gronlund B, Høgdall C, Hilden J, Engelholm SA, Høgdall EV and Hansen HH: Should CA-125 response criteria be preferred to Response Evaluation Criteria In Solid Tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 22: 4051-4058, 2004.
15. Gu P, Pan LL, Wu SQ, et al: CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma: a systematic review and meta-analysis. Eur J Radiol 71: 164-174, 2009.
16. Togashi K: Ovarian cancer: the clinical role of US, CT, and MRI. Eur Radiol 13 (Suppl 4): L87-L104, 2003.
17. Goonewardene TI, Hall MR and Rustin GJ: Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol 8: 813-821, 2007.
18. Aebi S and Castiglione M; ESMO Guidelines Working Group: Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20 (Suppl 4): 21-23, 2009.
19. Sturgeon CM, Duffy MJ, Stenman U-H, et al: National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem 54: e11-e79, 2008.
20. Bast RC Jr: Status of tumor markers in ovarian cancer screening. J Clin Oncol 21 (Suppl 10): s200-s205, 2003.
21. Moore RG, Jaube-Raughley M, Brown AK, et al: Comparison of a novel multiple marker assay vs. The Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol 203: e1-e6, 2010.
22. Schummer M, Drescher C, Forrest R, Gough S, Thorpe J, Hellström I, Hellström KE and Urban N: Evaluation of ovarian cancer remission markers HE4, MMP7 and Mesothelin by comparison to the established marker CA125. Gynecol Oncol 125: 65-69, 2012.
23. Hori SS and Gambhir SS: Mathematical model identifies blood biomarker-based early cancer detection strategies and limitations. Sci Transl Med 3: 109ra116, 2011.
24. Häfner N, Nicolaus K, Weiss S, Frey M, Diebolder H, Rengsberger M, Dürst M and Runnebaum IB: p53-autoantibody may be more sensitive than CA-125 in monitoring microscopic and macroscopic residual disease after primary therapy for epithelial ovarian cancer. J Cancer Res Clin Oncol 139: 1207-1210, 2013.
25. Rustin GJ: Follow-up with CA125 after primary therapy of advanced ovarian cancer has major implications for treatment outcome and trial performances and should not be routinely performed. Ann Oncol 22 (Suppl 8): viii45-viii48, 2011.
26. Rustin GJ, van der Burg ME, Griffin CL, et al: Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial. Lancet 376: 1155-1163, 2010.
27. Forstner R, Sala E, Kinkel K and Spencer JA; European Society of Urogenital Radiology: ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol 20: 2773-2780, 2010.
28. Coakley FV, Choi PH, Gougoutas CA, Pothuri B, Venkatraman E, Chi D, Bergman A and Hricak H: Peritoneal metastases: detection with spiral CT in patients with ovarian cancer. Radiology 223: 495-499, 2002.
29. Sala E, Kataoka M, Pandit-Taskar N, Ishill N, Mironov S, Moskowitz CS, Mironov O, Collins MA, Chi DS, Larson S and Hricak H: Recurrent ovarian cancer: use of contrast-enhanced CT and PET/CT to accurately localize tumor recurrence and to predict patients' survival. Radiology 257: 125-134, 2010.
30. Diniz Bizzo SM, Meira DD, Lima JM, Mororó Jda S, Casali-da-Rocha JC and Ornellas MH: Peritoneal VEGF burden as a predictor of cytoreductive surgery outcome in women with epithelial ovarian cancer. Int J Gynaecol Obstet 109: 113-117, 2010.
31. Kang S: The role of neoadjuvant chemotherapy in ovarian cancer patients with extensive tumor burden. J Gynecol Oncol 22: 299-300, 2011.
32. Midulla C, Manganaro L, Longo F, Viggiani V, Frati L, Granato T and Anastasi E: HE4 combined with MDCT imaging is a good marker in the evaluation of disease extension in advanced epithelial ovarian carcinoma. Tumour Biol 33: 1291-1298, 2012.